Related Experiment Videos
Antihypertensive therapy in experimental diabetes.
1Division of Nephrology and Hypertension, Oregon Health Sciences University, Portland.
Journal of the American Society of Nephrology : JASN
|October 1, 1992
Summary
Systemic hypertension accelerates diabetic kidney disease. Angiotensin-converting enzyme inhibitors show promise in slowing disease progression and protecting the kidneys in diabetic rats.
Area of Science:
- Nephrology
- Diabetology
- Cardiovascular Medicine
Background:
- Systemic hypertension is a key factor in diabetic glomerular disease progression.
- Understanding how hypertension worsens diabetic kidney disease is crucial.
- Investigating antihypertensive therapies may offer protective benefits.
Purpose of the Study:
- To investigate the mechanisms by which systemic hypertension exacerbates diabetic glomerulopathy.
- To evaluate the efficacy of antihypertensive therapy in mitigating diabetic kidney disease progression.
Main Methods:
- Studies were conducted using both normotensive and hypertensive diabetic rat models.
- Various antihypertensive regimens were administered to assess their impact.
Main Results:
- Certain antihypertensive regimens demonstrated effectiveness in slowing albuminuria and glomerular sclerosis.
- Angiotensin-converting enzyme inhibitors were consistently effective in protecting the kidneys.
- Other antihypertensive treatments showed less consistent results.
Conclusions:
- Systemic hypertension significantly contributes to the advancement of diabetic glomerular disease.
- Antihypertensive therapy, particularly with angiotensin-converting enzyme inhibitors, can slow disease progression and protect kidney function in diabetic conditions.
- Further research into the specific protective mechanisms of these inhibitors is warranted.